Literature DB >> 11676906

[Vesical uric acid lithiasis in a child with renal hypouricemia].

E Martín Hernández1, C Aparicio López, G Alvarez Calatayud, M A García Herrera.   

Abstract

We report a 12-month-old boy with renal hypouricemia who presented with crying due to obstructing vesicourethral uric acid stones. Metabolic study revealed persistent acidic urine with normal blood pH, and hypouricemia (1.4-1.7 mg/dl) with an increased ratio of uric acid clearance to creatinine clearance (24-32 %). Pyrazinamide produced no response but the patient showed a positive response to benzbromarone. These findings were consistent with a presecretory defect. No other tubular dysfunctions, such as renal glycosuria, aminoaciduria or phosphaturia were found. The patient underwent surgical treatment and was subsequently treated with potassium citrate. After a 2-year follow-up, he remains asymptomatic, despite persistent hyperuricosuria. To our knowledge, this is the youngest reported case of renal hypouricemia and lithiasis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11676906

Source DB:  PubMed          Journal:  An Esp Pediatr        ISSN: 0302-4342


  3 in total

1.  Clinical and functional characterization of URAT1 variants.

Authors:  Velibor Tasic; Ann Marie Hynes; Kenichiro Kitamura; Hae Il Cheong; Vladimir J Lozanovski; Zoran Gucev; Promsuk Jutabha; Naohiko Anzai; John A Sayer
Journal:  PLoS One       Date:  2011-12-16       Impact factor: 3.240

Review 2.  Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review.

Authors:  Abdul-Hamid Emwas; Claudio Luchinat; Paola Turano; Leonardo Tenori; Raja Roy; Reza M Salek; Danielle Ryan; Jasmeen S Merzaban; Rima Kaddurah-Daouk; Ana Carolina Zeri; G A Nagana Gowda; Daniel Raftery; Yulan Wang; Lorraine Brennan; David S Wishart
Journal:  Metabolomics       Date:  2014-11-21       Impact factor: 4.290

3.  NMR-Based Metabolomics.

Authors:  G A Nagana Gowda; Daniel Raftery
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.